Last reviewed · How we verify
NCT05065944
Comparing Pre-Anesthesia Evaluation Via Telemedicine Versus in Person for Surgical Patients at Moffitt Cancer Center
trial testing Telemedicine in Gynecologic Cancer in 106 participants. Completed in 9 August 2024.
19 August 2023
Quick facts
| Lead sponsor | H. Lee Moffitt Cancer Center and Research Institute |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 106 |
| Start date | 16 November 2021 |
| Primary completion | 19 August 2023 |
| Estimated completion | 9 August 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Telemedicine
- In Person Visit
Conditions studied
- Gynecologic Cancer — all drugs for Gynecologic Cancer →
- Prostate Cancer — all drugs for Prostate Cancer →
- Patient Satisfaction — all drugs for Patient Satisfaction →
Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Who can join
18 and older, any sex, with Gynecologic Cancer or Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a randomized controlled trial of patients scheduled for hysterectomy or prostatectomy surgeries who undergo a pre-anesthesia evaluation at Moffitt Cancer Center PreAnesthesia Testing (PAT) clinic. Traditionally, patients who met certain criteria based on type of surgery or comorbidities would undergo an in-person evaluation in our clinic. In order to make our patient's care more convenient and accessible, investigators have introduced telemedicine evaluation for a certain subset of patients meeting specific criteria. Investigators aim with this randomized trial to investigate the hypothesis that telemedicine pre-anesthesia evaluation is non-inferior to in-person evaluation from the standpoint of day of surgery cancellation rate.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05065944
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Telemedicine
Trials testing the same drug.
- NCT07059884 — Distance-Based Exercise to Preserve Function and Prevent Disability · NA · recruiting
- NCT07091617 — Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer · NA · recruiting
- NCT07027813 — Feasibility and Efficacy of Ambulance-Based m-Health for Pediatric Emergencies (FEAMER) Trial · NA · recruiting
- NCT07124546 — Acceptance and Commitment Therapy (ACT-HBC) for the Improvement of Cancer Distress in Patients With Hepatobiliary Cancer · NA · recruiting
- NCT06896539 — Telemedicine for Contraceptive Counselling- An Open Randomized Controlled Trial · NA · not yet recruiting
Other recruiting trials for Gynecologic Cancer
Currently open trials in the same condition.
- NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
- NCT07408349 — Guided Imagery of the Gynecological Cancer · NA · recruiting
- NCT07447050 — Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial · Phase 2 · recruiting
- NCT07173101 — Clinical Investigation of the Effects of Semiconductor Embedded Therapeutic Garments on Cancer-related Cognitive Impairm · Phase 2 · recruiting
- NCT07166042 — Guided Meditation During Radiation Therapy for Breast and Gynecological Malignancies · Phase 3 · recruiting
Other H. Lee Moffitt Cancer Center and Research Institute trials
Trials by the same sponsor.
- NCT05041335 — Wet Heparinized Suction for Abdominal Cancer · NA · not yet recruiting
- NCT07222995 — Hybrid Effectiveness-Implementation Trial to Integrate Precision Skin Cancer Risk Feedback in FQHCs · NA · recruiting
- NCT06047977 — Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid Tumors · Phase 1 · recruiting
- NCT06121180 — Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma · Phase 2 · recruiting
- NCT06193486 — Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05065944 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by H. Lee Moffitt Cancer Center and Research Institute
- Last refreshed: 23 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05065944.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing